Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00926939 · ClinicalTrials.gov registry record · NA
Technological Innovations in Behavioral Treatments for Cigarette Smoking
A NA study, sponsored by National Development and Research Institutes.
- Completed
- Registry status
- NA
- Development phase
- 96
- Enrollment target
NCT00926939: Completed NA study, sponsored by National Development and Research Institutes.
NCT00926939 is a NA study that has completed, run by National Development and Research Institutes. The registered enrollment target is 96 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00926939, a NA study, has completed, sponsored by National Development and Research Institutes.
- COMPLETED
- Registry status
- NA
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate a sustainable and broadly accessible treatment delivery model (Motiv8) for smoking cessation based on abstinence-reinforcement.
Interventions
- BEHAVIORAL Reinforcement for the abstinence of smoking
- BEHAVIORAL Reinforcement for submission of videos with CO sample
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2009-06 |
| Est. Completion | 2014-08 |
| Phase | NA |
What the finished NCT00926939 record still lists
NCT00926939 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Reinforcement for the abstinence of smoking is the first listed.
NCT00926939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00926939 about?
NCT00926939 is a clinical study titled "Technological Innovations in Behavioral Treatments for Cigarette Smoking". The purpose of the study is to evaluate a sustainable and broadly accessible treatment delivery model (Motiv8) for smoking cessation based on abstinence-reinforcement.
What is the current status of trial NCT00926939?
This trial is currently completed. It is a NA study. The enrollment target is 96 participants. The study started on 2009-06. Estimated completion is 2014-08.
What interventions are being tested in trial NCT00926939?
The interventions under investigation include: Reinforcement for the abstinence of smoking (BEHAVIORAL), Reinforcement for submission of videos with CO sample (BEHAVIORAL).
Who is sponsoring clinical trial NCT00926939?
This trial is sponsored by National Development and Research Institutes, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00926939's enrollment target sits among peer trials
96 925th of 2000 higher than 1,070 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia